SBIR/STTR Research Award
Drone-Delivered Naloxone System for Opioid Overdose Treatment
Award amount
$224,725Program and phase
STTR · Phase IAward year
2020Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- UAS ASSOCIATES, LLC
- Proposal award date
- 2020-07-01
- Contract end date
- 2021-06-30
- UEI
- C5A9AGFXYW81
- Solicitation number
- DA19-020
- Topic code
- NIDA
Research abstract
Program Director/Principal Investigator (Last, First, Middle): Ornato, Joseph, Pasquale
Summary
One hundred thirty Americans die from an opioid overdose (OD) daily. The key to improving this survival is
the timely delivery of the antidote naloxone. Current US Emergency Medical Services (EMS) systems are
often unable to deliver the life-saving drug fast enough manner to save the victim’s life. Our uniquely-qualified
team (Virginia UAS, LLC commercial drone pilot training instructors; a Virginia Commonwealth University
(VCU) faculty physician EMS medical director/jet and commercial drone pilot with extensive experience
leading high-impact, multicenter, prehospital NIH clinical trials; and VCU engineers with experience in
development and commercialization of drone hardware and software) has developed a novel prototype drone
system that is interfaced to Richmond’s 9-1-1 dispatch computer. The system automatically loads a 9-1-1
bystander caller’s GPS phone location into a drone and launches it to the scene of an opioid OD carrying a
lightweight, removable, patent-pending, real-time audio/video package (COMMRx) containing naloxone nasal
spray. Just five drones in the City of Richmond could ensure delivery of the naloxone package to bystanders
in ≤2 min as EMS first responders begin racing to the scene. Trained 9-1-1 pilot dispatchers would direct the
bystander to remove COMMRx from the drone, take it to the victim, and administer the naloxone spray long
before first responders can physically reach the victim. This Phase I project proposes to: 1) finalize the
system customization; 2) train/FAA-certify seven 9-1-1 dispatchers drone pilots; and 3) perform realistic
simulation testing of the system to guide design of a Phase II clinical trial to take place in Richmond,
Henrico/Chesterfield counties, and Roanoke, VA. This novel system developed and executed by a uniquely
qualified team shifts the paradigm of prehospital emergency care delivery by empowering and directing
laypersons to initiate time-dependent, life-saving treatment to opioid OD victims long before EMS personnel
can physically treat the patient. Our commercial goal is to expand our flight school business to provide
similar capability throughout the 5,783 9-1-1 centers nationally.
OMB No. 0925-0001/0002 (Rev. 01/18 Approved Through 03/31/2020) Page Continuation Format PageProgram Director/Principal Investigator (Last, First, Middle): Ornato, Joseph, Pasquale
Emergency Medical Services (EMS) systems can’t reliably deliver life-saving naloxone antidote treatment
needed to save opioid overdose (OD) victims because first responders can’t physically get there in time. We
propose to finalize development of our novel, rapid, drone delivery system that can deliver naloxone spray
antidote and direct lay bystanders to administer the life-saving treatment. Our proposal can be implemented
cost-effectively at 9-1-1 centers nationwide to mitigate the mortality burden from the ongoing opioid crisis.
OMB No. 0925-0001/0002 (Rev. 01/18 Approved Through 03/31/2020) Page Continuation Format Page
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Wearable Wireless Respiratory Monitoring System that Detects and Predicts Opioid Induced Respiratory Depression
- Building and testing the Life Enhancement and Advocacy Programming digital training tool (LEAPLink) to better serve people with lived experience of homelessness and substance use disorder
- A digital intervention to decrease self-stigma among pregnant and postpartum women with opioid use disorder
- Development of medication for the treatment of respiratory depression due to opioid (prescribed or illicit) overdose/multidrug (polysubstance) overdose in a hospital or community setting.
- Creation and Validation of the Dose-Opioid-Source Evaluation tool (DOSE) - a Robust Opioid Use Clinical Outcome Assessment for Qualification as an FDA Medical Device Development Tool (MDDT)